Genmab — December 2024

[E_L]

small new Ph2
trial - Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma https://clinicaltrials.gov/study/NCT06575686

[ProinvestorNEWS]

Genmab får hævet anbefaling til "market perform" af Bernstein https://proinvestor.com/investornyt/1256245/genmab-far-haevet-anbefaling-til-market-perform-af-bernstein

[E_L]

every investment fund suddenly underweight Danish pharma and biotech, just like that...

[E_L]

"underweight" ,
pun intended

[Sukkeralf]

We could hope for some new shares holders if people get tired of obesity stocks for a while

[E_L]

yes, feel sorry for the Novo holders, but you are very welcome here at genmab...

[Bulder]

Especially those who had bull x 10

[Bulder]

On the other hand bear x 10 is up 180%. But in Nordnet it was only 2 persons. 66 persons had Bull x 10.

[Bulder]

This morning somebody sold 900 bear x10 for 44 dkk

[Bulder]

2 hours later the Price was 135. Hard luck.

[E_L]

the joys of leverage...pfff... also, horrible timing to bring this news on what is possibly the last active trading day of the year for many and also a big option expiration...

[E_L]

Japanese GEN1042 trial adds 2 arms , but i can not immediately see the difference between cohorts 1&2 and 3&4... https://clinicaltrials.gov/study/NCT06057038?tab=history&a=13&b=14&compareMode=sideBySide#version-content-panel

[E_L]

always glad to see activity on GEN1042, as we are waiting to hear what will happen to this program... activity means it isn't shut down yet lol

[E_L]

maybe they made a mistake and they forgot to add 'Dose Expansion' of something for cohort 3&4

[lahn1]

It a relief to see you still have some positivity in you EL

[lahn1]

Currently returning some of the kids Christmas presents at the store. Maybe next year

[E_L]

[Solsen]

JW er optimistisk https://www.linkedin.com/posts/janvandewinkel_happyholidays-activity-7275886998362488834-VYIk?utm_source=share&utm_medium=member_ios

[GeorgeBest]

Tjaa

[GeorgeBest]

Det er lang tid siden man som aktionær i Genmab har haft en følelse af “outstanding year”